cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals. While revenue growth and strategic acquisitions like Bluebird Botanicals are positive, declining gross margins and increased operational losses raise concerns. The Q&A indicated management's optimism about future synergies and improved EBITDA, but lacked clarity on key metrics and timelines. The cautious stance on reverse stock split and challenges in regulatory environments add uncertainty. Given these factors, the stock price reaction is likely to remain stable, with no strong catalysts for significant movement in either direction over the next two weeks.
Key Financial Performance
Net Sales $5.6 million, a 19% increase year-over-year from $4.7 million in the prior year period and a 12% sequential increase from the first quarter of fiscal 2026. The growth was driven by core business growth of $0.5 million year-over-year and $300,000 sequentially, excluding the Bluebird Botanicals acquisition.
Gross Margin 58%, down from 62% year-over-year. The decline was due to a shift in revenue mix towards more wholesale sales, including Oasis, and incremental costs related to state-level requirements such as repacking and new testing.
Loss from Operations Approximately $801,000, compared to a loss of $486,000 in the prior year period. Excluding a one-time noncash stock vesting, the loss was $405,000. The increase in loss was attributed to transition costs and integration expenses from the Bluebird Botanicals acquisition and strategic investments in the CMS BEI program.
Net Loss Attributable to Common Shareholders Approximately $876,000 or $0.08 per share, compared to a net loss of approximately $1.4 million or $1.90 per share in the prior year quarter. The improvement was primarily driven by the elimination of the Series A preferred dividend during fiscal 2025 and its conversion into common stock.
Adjusted Non-GAAP EBITDA Loss $220,000, driven by added payroll and other expenses related to the Bluebird acquisition without the benefit of a full quarter of Bluebird revenue, as well as strategic investments in the CMS BEI program.
Cash Used in Operating Activities Approximately $723,000, reflecting a $435,000 build in accounts receivable tied to revenue growth and wholesale term customers, and an incremental $240,000 inventory build to support overall business growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of Bluebird Botanicals: cbdMD acquired Bluebird Botanicals, a respected CBD brand, marking its first acquisition in years. This acquisition broadens cbdMD's portfolio, adds a loyal customer base, and complements its existing THC-free formulations with Bluebird's full-spectrum CBD products.
New Product Rollouts: cbdMD plans to roll out additional products under the Bluebird Botanicals brand to capture cost and revenue synergies.
Revenue Growth: Net sales reached $5.6 million, a 19% year-over-year increase and a 12% sequential increase from the first quarter of 2026. Core business revenue also grew, excluding Bluebird Botanicals.
Wholesale Channel Expansion: Wholesale revenue grew to 33% of total revenue, up 65% year-over-year, driven by the cbdMD brand and Oasis TSC beverage brand.
Operational Efficiency: Gross margin decreased to 58% from 62% due to a shift in revenue mix and incremental costs from state-level regulatory changes. cbdMD is implementing initiatives to improve product quality, formulas, and gross margins.
CMS BEI Program Investment: cbdMD accelerated its entry into the CMS substance access pathway, incurring near-term costs to establish a position in this federally supported Medicare channel.
Regulatory Engagement: cbdMD is actively supporting bipartisan efforts for federal hemp regulation and engaging with policymakers to establish a science-based framework.
State-Level Compliance: The company is managing costs and operational challenges due to shifting state-level regulations, including packaging changes and new testing requirements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Acquisition Costs and Integration Challenges: The acquisition of Bluebird Botanicals was a drag on earnings during the second quarter due to transition costs and integration expenses. This impacted financial performance without the full benefit of Bluebird's revenue.
State-Level Regulatory Volatility: Changing state regulations have led to ongoing packaging changes, repacking costs, and new testing requirements. These changes create additional operational expenses and customer confusion, narrowing product availability and sales opportunities.
Federal Regulatory Uncertainty: The company faces uncertainty regarding federal hemp regulations, including the potential impact of the November 2026 effective date of the act. This requires contingency planning and additional costs for reformulation, packaging, and supply chain adjustments.
CMS BEI Program Costs: Accelerated investment in the CMS substance access pathway has led to near-term costs, impacting profitability. The company anticipates a long-term opportunity but acknowledges the current financial strain.
Gross Margin Pressure: Gross margins decreased from 62% to 58% due to a shift in revenue mix toward wholesale and incremental costs from state-level regulatory changes. This impacts overall profitability.
Operational Costs from Revenue Growth: Increased accounts receivable and inventory build tied to revenue growth have led to higher cash usage in operating activities, impacting liquidity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Earnings Growth: The company expects the acquisition of Bluebird Botanicals to transition from an earnings drag in Q2 to a positive contributor in Q3 2026, both in terms of revenue and earnings. The core business is projected to continue its sequential growth, supported by high-velocity SKUs, disciplined customer acquisition, and wholesale expansion.
CMS BEI Program: cbdMD has accelerated its entry into the CMS substance access pathway, expecting provider adoption to develop over the next 12 to 18 months. The company is investing in clinical evidence and healthcare channels to establish itself as a trusted supplier in this federally supported Medicare pathway.
Regulatory Environment: The company is actively engaging in federal legislative efforts to establish a workable framework for hemp regulation. It is also preparing for the November 2026 effective date of the act by planning for reformulation, new ingredients, packaging adjustments, and supply chain flexibility to adapt to potential regulatory outcomes.
M&A Strategy: cbdMD plans to evaluate additional disciplined and accretive M&A opportunities in the hemp and adjacent health and wellness categories, leveraging its infrastructure and marketing capabilities.
Operational Adjustments: The company is managing through state-level regulatory changes, which include packaging, testing requirements, and compliance costs. It is building cost discipline and operational flexibility to absorb these challenges.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Series A preferred dividend elimination: The company eliminated its Series A preferred dividend during fiscal 2025, which contributed to a substantial improvement in net loss per share.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of the 11% organic revenue growth in the March quarter was attributable to Herbal Oasis versus the core CBD businesses?
A:The growth was split between the core CBD businesses and Herbal Oasis, with a reasonable amount attributed to Herbal Oasis.
Q:Will there be more granularity in the Q regarding the impact of Herbal Oasis, and will it be reported later in the fiscal year?
A:The company has not segregated that category yet but will evaluate segmentation as growth continues.
Q:How does the company plan to use its balance sheet and liquidity profile to support growth opportunities given the cash burn and current cash position?
A:The company made inventory investments ahead of growth and plans to be more efficient with inventory management. They anticipate improved EBITDA and reduced working capital requirements moving forward.
Q:What is the update on the reverse stock split proposal passed at the Annual Shareholders Meeting?
A:The reverse stock split is a precautionary measure with no current plan to execute it. It is available as a tool to react quickly if needed due to market volatility.
Q:Does the restriction on trading stocks under $1 or $5 by broker-dealers affect the urgency to implement the reverse stock split?
A:The company is continuing to evaluate this and will do so throughout the year.
Q:What is the update on realizing supply chain or shared service synergies with Bluebird Botanicals, and will it be accretive to the bottom line in the fiscal third quarter?
A:The company has incurred transaction and transition costs but is realizing synergies and integrating supply chains. They expect Bluebird Botanicals to contribute to the bottom line in the fiscal third quarter.
Q:Is the company still evaluating SKU overlap and potential rationalization?
A:Yes, the company is managing SKU overlap through inventory sell-through and expects this process to evolve over the year.
Q:What are the next steps and challenges for the BEI channel initiative, and when could it contribute to material growth?
A:The initiative faces challenges such as navigating healthcare regulations, educating the medical community, and proving economic benefits. Significant work is needed, and the timeline for material growth is uncertain.
Q:How is the company dealing with challenges from changing statewide regulations, and which products are most impacted?
A:The company is focusing on staying agile with supply chain and inventory management. Full spectrum products containing hemp-derived Delta-9 are most impacted, particularly in states like Alabama where regulations have changed.
Q:What are the incremental free cash flow margins on sales as the company scales, and what is the breakeven quarterly revenue?
A:The company’s breakeven quarterly revenue is well below $7 million, and incremental free cash flow margins are higher than 30%, though exact figures were not committed to.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact contribution of Herbal Oasis to revenue growth, the timeline for reverse stock split implementation, and the precise breakeven revenue or free cash flow margins. Responses were often general and lacked numerical specificity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACOs others
Act Hemp
BEI
Botanicals
CMS substance
Executive Officer
Officer Chief
Officer Treasurer
Ronan
SEC website
Treasurer Secretary
Update
Wholesale
benefit
build
case
cbdMD brand
cbdMD statement
change
channel
conference
core cbdMD
decision
evidence
financials
loss share
mix
opportunity health
pathway
quality safety
science
spectrum
stock loss
substance access
testing requirement
today date
work
YCBD Transcript
cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript
Unknown5-14
The earnings call presented mixed signals. While revenue growth and strategic acquisitions like Bluebird Botanicals are positive, declining gross margins and increased operational losses raise concerns. The Q&A indicated management's optimism about future synergies and improved EBITDA, but lacked clarity on key metrics and timelines. The cautious stance on reverse stock split and challenges in regulatory environments add uncertainty. Given these factors, the stock price reaction is likely to remain stable, with no strong catalysts for significant movement in either direction over the next two weeks.
cbdMD, Inc. (YCBD) Q1 2026 Earnings Call Transcript
Unknown2-17
The earnings call reflects mixed signals: a 12% revenue increase and improved liquidity are positive, but declining margins, a net loss, and integration risks weigh negatively. The Q&A reveals uncertainty, particularly around the Herbal Oasis product line, and management's vague responses may concern investors. The lack of market cap data limits assessment of stock reaction magnitude, but overall, the sentiment aligns with a neutral prediction given the balanced positives and negatives.
cbdMD, Inc. (YCBD) Q4 2025 Earnings Call Transcript
Unknown12-19
The earnings call presents a mixed picture: improved operating results and gross margin are positive, but declining e-commerce sales and marketing inefficiencies are concerning. The Q&A section reveals cautious optimism about regulatory developments but lacks clarity on strategic plans. While the elimination of preferred dividend obligations and growth in wholesale sales are positives, the company's reliance on equity financing and potential dilution remain concerns. Overall, the sentiment is neutral due to balanced positive and negative aspects, with no clear catalyst for a strong stock price movement in either direction.
cbdMD, Inc. (AMEX:YCBD) Q2 2025 Earnings Call Transcript
Unknown5-17
The earnings call reveals mixed signals: a slight revenue increase and improved cost structure are positive, but regulatory challenges and liquidity risks temper optimism. The new product expansion and capital structure improvements could yield future benefits, yet current financial constraints and market competition pose challenges. Analysts' cautious sentiment in the Q&A further supports a neutral outlook.
YCBD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
